Literature DB >> 2845729

Differential cyclic AMP responses to calcitonin among human ovarian carcinoma cell lines: a calcitonin-responsive line derived from a rare tumor type.

K S Upchurch1, L M Parker, R E Scully, S M Krane.   

Abstract

Several human tumor cell lines have been reported to have specific receptors for calcitonin (CT) and CT-responsive adenylate cyclase. In order to correlate patterns of responsiveness to CT, parathyroid hormone (PTH) and prostaglandin E2 (PGE2) with tumor morphology and intermediate filament protein expression, we examined four human ovarian tumor cell lines (BIN-16, BIN-22, BIN-53, BIN-67) which had been cultured from cells of metastatic foci. In two cell lines (BIN-53 and -16) there were small increases in cAMP content after exposure to CT and in three cell lines (BIN-53, -16, and -22) larger increases with PGE2. There was no cAMP response in any of the cells to PTH. In BIN-67 cells, however, CT induced a striking (greater than 20-fold) increase in cAMP content. Histologically, the CT-nonresponsive tumor lines were derived from serous adenocarcinomas while the CT-responsive tumor line was from a rare small cell carcinoma. Gel electrophoretic and immunofluorescence microscopic analyses had previously disclosed that the CT-nonresponsive cell lines contained high levels of simple epithelial keratins and no or very low levels of vimentin (characteristic of ovarian surface epithelial cells), while the CT-responsive cell line contained almost exclusively vimentin. Thus, cells cultured from a rare type of ovarian tumor were CT-responsive and were distinguishable from CT-nonresponsive ovarian tumor cells by initial tumor histology and intermediate filament protein expression.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2845729     DOI: 10.1002/jbmr.5650010309

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  8 in total

Review 1.  Calcitonin and calcitonin receptors: bone and beyond.

Authors:  M Pondel
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

2.  Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.

Authors:  Leora Witkowski; Jian Carrot-Zhang; Steffen Albrecht; Somayyeh Fahiminiya; Nancy Hamel; Eva Tomiak; David Grynspan; Emmanouil Saloustros; Javad Nadaf; Barbara Rivera; Catherine Gilpin; Ester Castellsagué; Rachel Silva-Smith; François Plourde; Mona Wu; Avi Saskin; Madeleine Arseneault; Rouzan G Karabakhtsian; Elizabeth A Reilly; Frederick R Ueland; Anna Margiolaki; Kitty Pavlakis; Sharon M Castellino; Janez Lamovec; Helen J Mackay; Lawrence M Roth; Thomas M Ulbright; Tracey A Bender; Vassilis Georgoulias; Michel Longy; Andrew Berchuck; Marc Tischkowitz; Inga Nagel; Reiner Siebert; Colin J R Stewart; Jocelyne Arseneau; W Glenn McCluggage; Blaise A Clarke; Yasser Riazalhosseini; Martin Hasselblatt; Jacek Majewski; William D Foulkes
Journal:  Nat Genet       Date:  2014-03-23       Impact factor: 38.330

3.  Calcitonin (but not calcitonin gene-related peptide) increases mouse bone cell proliferation in a dose-dependent manner, and increases mouse bone formation, alone and in combination with fluoride.

Authors:  J R Farley; S L Hall; N M Tarbaux
Journal:  Calcif Tissue Int       Date:  1989-10       Impact factor: 4.333

4.  Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line.

Authors:  A H Gorn; H Y Lin; M Yamin; P E Auron; M R Flannery; D R Tapp; C A Manning; H F Lodish; S M Krane; S R Goldring
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

5.  Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics.

Authors:  Lisa F Gamwell; Karen Gambaro; Maria Merziotis; Colleen Crane; Suzanna L Arcand; Valerie Bourada; Christopher Davis; Jeremy A Squire; David G Huntsman; Patricia N Tonin; Barbara C Vanderhyden
Journal:  Orphanet J Rare Dis       Date:  2013-02-21       Impact factor: 4.123

6.  c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.

Authors:  Anna Otte; Finn Rauprich; Juliane von der Ohe; Yuanyuan Yang; Friedrich Kommoss; Friedrich Feuerhake; Peter Hillemanns; Ralf Hass
Journal:  Oncotarget       Date:  2015-10-13

7.  CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.

Authors:  Yibo Xue; Brian Meehan; Elizabeth Macdonald; Sriram Venneti; Xue Qing D Wang; Leora Witkowski; Petar Jelinic; Tim Kong; Daniel Martinez; Geneviève Morin; Michelle Firlit; Atefeh Abedini; Radia M Johnson; Regina Cencic; Jay Patibandla; Hongbo Chen; Andreas I Papadakis; Aurelie Auguste; Iris de Rink; Ron M Kerkhoven; Nicholas Bertos; Walter H Gotlieb; Blaise A Clarke; Alexandra Leary; Michael Witcher; Marie-Christine Guiot; Jerry Pelletier; Josée Dostie; Morag Park; Alexander R Judkins; Ralf Hass; Douglas A Levine; Janusz Rak; Barbara Vanderhyden; William D Foulkes; Sidong Huang
Journal:  Nat Commun       Date:  2019-02-04       Impact factor: 14.919

8.  In vitro and in vivo therapeutic approach for a small cell carcinoma of the ovary hypercalcaemic type using a SCCOHT-1 cellular model.

Authors:  Anna Otte; Finn Rauprich; Peter Hillemanns; Tjoung-Won Park-Simon; Juliane von der Ohe; Ralf Hass
Journal:  Orphanet J Rare Dis       Date:  2014-08-08       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.